SUBSCRIBE
SUBSCRIBE

Panbela Therapeutics Inc.

IN THE PRESS
Press Releases
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
October 31, 2024
 · 
6 min read
Press Releases
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
September 25, 2024
 · 
8 min read
Press Releases
Panbela Provides Business Update and Reports Q2 2024 Financial Results
August 14, 2024
 · 
13 min read
Press Releases
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
July 31, 2024
 · 
6 min read
Business
Panbela Provides Business Update and Reports Q1 2024 Financial Results
May 15, 2024
 · 
13 min read
Policy
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 6, 2024
 · 
7 min read
Business
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
May 1, 2024
 · 
6 min read
BioMidwest
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
April 30, 2024
 · 
6 min read
BioMidwest
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025Trial’s lower-than-expected event rate suggests improved survival outcomes
April 22, 2024
 · 
8 min read
BioMidwest
Panbela Announces Poster Presentation at American Association for Cancer Research:Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
April 18, 2024
 · 
8 min read
Load More
JOBS